Comparison of the Efficacy and Safety of 2 Regimens of Taxotere Combined with Epirubicin in the Neoadju-vant Chemotherapy of Breast Cancer / 中国药房

ABSTRACT

OBJECTIVE:To observe the short-term efficacy and toxicity reaction of 2 regimens of taxotere combined with epi-rubicin in the neoadjuvant chemotherapy of breast cancer. METHODS:78 patients with locally advanced breast cancer were random-ly divided into TEC group(45 cases)and TE group(33 cases). TEC group was treated with taxotere 75 mg/m2 by intravenous in-jection,d1+epirubicin 60 mg/m2 by intravenous injection,d1+cyclophosphamide 500 mg/m2 by intravenous injection d1. TE group was treated with taxotere 75 mg/m2 by intravenous injection,d1+epirubicin 60 mg/m2 by intravenous injection,d1. 21 days were a treatment course for 2 groups,and there were totally 4-6 courses. In the 2 groups,efficacy and toxicity reaction were evaluated af-ter 4 weeks at least,and survival rate of 6 months was followed-up. RESULTS:The differences were not statistically significant in the short-term efficacy and toxicity reaction and survival rate between 2 groups (P>0.05). CONCLUSIONS:TEC and TC have similar short-term efficacy and safety in the treatment of locally advanced breast cancer. Both of them can be used as adjuvant medi-cines for neoadjuvant chemotherapy.